Cargando…

Lung-selective mRNA delivery of synthetic lipid nanoparticles for the treatment of pulmonary lymphangioleiomyomatosis

Safe and efficacious systemic delivery of messenger RNA (mRNA) to specific organs and cells in vivo remains the major challenge in the development of mRNA-based therapeutics. Targeting of systemically administered lipid nanoparticles (LNPs) coformulated with mRNA has largely been confined to the liv...

Descripción completa

Detalles Bibliográficos
Autores principales:	Qiu, Min, Tang, Yan, Chen, Jinjin, Muriph, Rachel, Ye, Zhongfeng, Huang, Changfeng, Evans, Jason, Henske, Elizabeth P., Xu, Qiaobing
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	National Academy of Sciences 2022
Materias:	Biological Sciences
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8872770/ https://www.ncbi.nlm.nih.gov/pubmed/35173043 http://dx.doi.org/10.1073/pnas.2116271119

Ejemplares similares

Lipid nanoparticle-mediated lymph node–targeting delivery of mRNA cancer vaccine elicits robust CD8(+) T cell response
por: Chen, Jinjin, et al.
Publicado: (2022)

Tailoring combinatorial lipid nanoparticles for intracellular delivery of nucleic acids, proteins, and drugs
por: Li, Yamin, et al.
Publicado: (2022)

Synthetic and nature-derived lipid nanoparticles for neural regeneration
por: Takeda, Yuji S., et al.
Publicado: (2015)

Lymphangioleiomyomatosis: circulating levels of FGF23 and pulmonary diffusion
por: Esposito, Anthony J, et al.
Publicado: (2023)

Towards personalised therapy for lymphangioleiomyomatosis: lessons from cancer
por: El-Chemaly, Souheil, et al.
Publicado: (2014)

Efficient Delivery of Antisense Oligonucleotides Using Bioreducible Lipid Nanoparticles In Vitro and In Vivo
por: Yang, Liu, et al.
Publicado: (2020)

Synthetic bioreducible lipid‐based nanoparticles for miRNA delivery to mesenchymal stem cells to induce neuronal differentiation
por: Takeda, Yuji S., et al.
Publicado: (2016)

The effect of mTOR inhibitors on respiratory infections in lymphangioleiomyomatosis
por: Courtwright, Andrew M., et al.
Publicado: (2017)

A high-throughput approach of screening nanoparticles for targeted delivery of mRNA
por: Khirallah, Jennifer, et al.
Publicado: (2023)

Coexistence of pulmonary lymphangioleiomyomatosis and pulmonary angiomyolipoma
por: Sun, Xuefeng, et al.
Publicado: (2016)

Pulmonary lymphangioleiomyomatosis in a male.
por: Kang, H. W., et al.
Publicado: (1991)

Lipid nanoparticles for mRNA delivery
por: Hou, Xucheng, et al.
Publicado: (2021)

Management of refractory chylothorax in pulmonary lymphangioleiomyomatosis
por: Ellender, Claire M, et al.
Publicado: (2015)

In situ cancer vaccination using lipidoid nanoparticles
por: Chen, Jinjin, et al.
Publicado: (2021)

Aerosolizable Lipid Nanoparticles for Pulmonary Delivery of mRNA through Design of Experiments
por: Zhang, Hairui, et al.
Publicado: (2020)

Ionizable lipid nanoparticles for in utero mRNA delivery
por: Riley, Rachel S., et al.
Publicado: (2021)

mTORC1 hyperactivation in lymphangioleiomyomatosis leads to ACE2 upregulation in type II pneumocytes: implications for COVID-19
por: Tang, Yan, et al.
Publicado: (2021)

Unilateral giant renal angiomyolipoma and pulmonary lymphangioleiomyomatosis
por: de Campos, Fernando Peixoto Ferraz, et al.
Publicado: (2013)

Pulmonary lymphangioleiomyomatosis masquerading as unilateral heterogeneous emphysema
por: Srinivasan, Lakshmi, et al.
Publicado: (2020)

Pulmonary lymphangioleiomyomatosis with an associated giant renal angiomyolipoma
por: John, Jeff, et al.
Publicado: (2022)

Bioinformatics analysis of inflammation and oncology in pulmonary lymphangioleiomyomatosis
por: Su, Wanchun, et al.
Publicado: (2022)

Pulmonary Langerhans Cell Histiocytosis Masquerading as Lymphangioleiomyomatosis
por: Patel, Priya, et al.
Publicado: (2023)

Protease activity sensors enable real-time treatment response monitoring in lymphangioleiomyomatosis
por: Kirkpatrick, Jesse D., et al.
Publicado: (2022)

Management of lymphangioleiomyomatosis
por: Taveira-DaSilva, Angelo M., et al.
Publicado: (2014)

Lymphangioleiomyomatosis (LAM)
Publicado: (2017)

Delivery of mRNA to platelets using lipid nanoparticles
por: Novakowski, S., et al.
Publicado: (2019)

Recent Advances in Lipid Nanoparticles for Delivery of mRNA
por: Yang, Lei, et al.
Publicado: (2022)

MicroRNA-21 is Induced by Rapamycin in a Model of Tuberous Sclerosis (TSC) and Lymphangioleiomyomatosis (LAM)
por: Trindade, Anil J., et al.
Publicado: (2013)

Pulmonary arterial involvement leading to alveolar hemorrhage in lymphangioleiomyomatosis
por: Baldi, Bruno Guedes, et al.
Publicado: (2011)

New insights in lymphangioleiomyomatosis and pulmonary Langerhans cell histiocytosis
por: Torre, Olga, et al.
Publicado: (2017)

Estradiol Augments the Production and Actions of Polymorphonuclear Cells to Promote Lymphangioleiomyomatosis (LAM) Progression
por: Minor, Briaunna M N, et al.
Publicado: (2021)

RF19 | PSUN351 Glycoprotein-NMB (GPNMB) is Pro-Tumorigenic in Lymphangioleiomyomatosis (LAM)
por: Gibbons, Erin, et al.
Publicado: (2022)

Serum endostatin levels are associated with diffusion capacity and with tuberous sclerosis- associated lymphangioleiomyomatosis
por: Lamattina, Anthony M., et al.
Publicado: (2019)

Lymphangioleiomyomatosis: an explosive presentation of a rare disease
por: Pais, Faye, et al.
Publicado: (2017)

Lipid Nanoparticles for Organ-Specific mRNA Therapeutic Delivery
por: Żak, Magdalena M., et al.
Publicado: (2021)

Lipid Nanoparticles for mRNA Delivery to Enhance Cancer Immunotherapy
por: Wang, Hong-Li, et al.
Publicado: (2022)

Treatment of lymphangioleiomyomatosis and Camões
por: Rufino, Rogério
Publicado: (2015)

Methylprednisolone in the treatment of lymphangioleiomyomatosis
por: Dale, Ventour, et al.
Publicado: (2022)

Chylothorax, in the Spotlight of Lymphangioleiomyomatosis
por: Gámez-Baeza, Pablo, et al.
Publicado: (2022)

Is sirolimus a therapeutic option for patients with progressive pulmonary lymphangioleiomyomatosis?
por: Neurohr, Claus, et al.
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_12vml5cafs9epq17uejmvhopj0